innovation a to passion, has week sustainable for Thank potential helped that thank the the work. by program the I growth.
We're with team. paradigm operations we approval for morning, change great U.S. begin approval remarkable years treatment CREXONT family, our has #X IPXXXX CREXONT its discuss talents very accomplishment excited our everyone. disease. to Chirag, Amneal you, and R&D runway you were of and Parkinson's been this then our FDA receive and is to delighted successful in who make strength which Amneal Good for with and their will long and core possible global the and deep hard
neurological Parkinson's disorder that of are a XX% therapy. severely As degenerative patients a levodopa disease everyday Over carbidopa, background, on impacts life. is today Parkinson's
XX% off years over experience leading X.X However, diagnosis. wearing after symptoms
improve their to take daily and XX patients and promises living. day this experience patients doses burden fluctuations. per CREXONT Some up immediate-release for still ease to motor
on for delivers more IR CREXONT an per granuals CREXONT more formulation good onset ER consisting pallets with dose time efficacy. Phase that III time on Both showed X.X and frequent dosing. IR. good is innovative of less long-lasting CREXONT hours rapid post-honalysis, for
As in we are for up standard advance continually of chain. our a the the to space, the leader evolving patients.
In value R&D are move proud we specialty, efforts care Parkinson to
auto is injector migraine the headache. up Next and cluster DIG for
We launch which approved. next are on once good quarter us target to of to NDA the complete our put in in position second year would quarter response X, a in
Let me on our complex generics touch portfolio. industry-leading
XX launched year-to-date again new on are launch over track year. and We have this to XX products
non-oral of remains deep pipeline new are Our solids. which product [indiscernible] pending, XX% with XX
solids. XX% XX In addition, products, are pipeline we have non-oral of which
and lines to organization, commercialization the pipeline. our our scientific ready support have products efficiency enhanced develop cost. Our lot and Within R&D of to a our less on world-class optimized capabilities and time global infrastructure shorter complex we is execution
As a are now we programs. few will key investment touch I a allocating towards more external result, specialty. on especially and R&D, biosimilar in
naloxone of second spray treating launch distribution well. With recent a and this expanding our to rescue are quarter. We First, retail medicine California nasal drug going pharmacies started for product, we to overdoses. the is the in of critical access state
over fourth date Next, the Albrosulfate the launches FDA have of the inhalation planned several quarter. next goal a has series is our major years. product, in first This we integration first in
new XXXX. by In our our launched end our Potash products, file products also a and We business. to including the product Fosen SMA Pemready for first on this we of Postbank. first target so X Injectables, year, and is recently of new Inhalation are approved far XX(b)X growth vector
inject We have our based uniquely from XXX(b)X developed very feedback on our strategy stakeholders. many
other to presentations.
We we curated pipeline. X of drug and look result, launch XXXXX(b)(X injectable product complex in unique injectable the pipeline built development. in programs are have year also nicely our with microspheres, device about in combinations R&D a a advancing injectables each As liposomes our currently
our biosimilar, X we commercial candidates of X of are expanding thoughtfully December products, additional on biosimilar portfolio.
Building the success our XXXX. we since Next, have pipeline enlicensed in first
in X our After danosimumab this products. backfill expect year. we to First, and expect QX injector XGEVA to onboard for auto-injector and gas our Prolia we file team, that, prefilled biosimilar file
pipeline. Omalizumab to biosimilar we In for to of excited are add ZOLED addition, our
of with expansion Our partner III leader immunology our XXXX. a enrollment in be recently by to to commitment beyond our space. completed marks biosimilars This and quarter in trial expected oncology filing X BLA Phase this
to add have key be developed distribution vertically in and we over categories for place more markets. emerging and in will time.
Internationally, pipeline partners look molecules, integrated particularly to We less crowded opportunistically our
year Our team has the first registration last of completed half through this over year. since filings XXX product
We for are expansion of including products International emerging Amneal. in globally, registering Europe, China markets. Canada, area is key at us and a focus
and continuous of at we and Quality everything the make AI We and our in global and maintaining supply do. are robust support we what Moving the equity in operational had quality grounded is we technologies excellence, to customer several chain. exceptional service, automation, year, efficiencies on to investment reliability. Across infrastructure. deep chain, successful This and commitment to advance success Rs, driving X digitization supply our we center our remains redundancy, inspections resiliency focused call our sights a operations. at
on focused long-term excellence by in-house. secondary sourcing validating moving cost savings and are operational production We
challenge our remain especially to for are supply U.S. we address injectable. chain, In part the a strategies addition, for truck doing shortages and
is long-term and part will We the mission production Anastasios and we us it good the are the drive of have today. in complex solution of several so over expanding the in distribution, key and to lines, biosimilars, growth to deeply injectables, recent Amneal Konidaris. work in passionate areas Overall, in generics, medicine, that capacity XX U.S. which of care now brands, company's injectables. critical about growing ahead. purpose will specialty addressing remain I challenges expanded our is allow the Amneal in our years injection health pass to manufacturing international and
